UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/800,448	03/05/2001	Santu Bandyopadhyay	A34065	2808	
	21003 7590 08/25/2008 BAKER BOTTS L.L.P.			EXAMINER	
30 ROCKEFEL	LER PLAZA	EWOLDT, GERALD R			
44TH FLOOR NEW YORK, NY 10112-4498			ART UNIT	PAPER NUMBER	
			1644		
			NOTIFICATION DATE	DELIVERY MODE	
			08/25/2008	ELECTRONIC	

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

DLNYDOCKET@BAKERBOTTS.COM

	Application No.	Applicant(s)	
	09/800,448	BANDYOPADHYAY ET AL.	
Office Action Summary	Examiner	Art Unit	
	G. R. Ewoldt, Ph.D.	1644	
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING Description of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tin I will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on <u>27 M</u> This action is <b>FINAL</b> . 2b) ☑ This action is application is in condition for allowed closed in accordance with the practice under	s action is non-final. ance except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) 65-75 is/are pending in the application 4a) Of the above claim(s) is/are withdrage 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 65-75 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or comparison.	awn from consideration.		
9)☐ The specification is objected to by the Examin	er.		
10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	e drawing(s) be held in abeyance. Section is required if the drawing(s) is ob-	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat* See the attached detailed Office action for a list	nts have been received. nts have been received in Applicationity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08)  Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate	

Application/Control Number: 09/800,448

Art Unit: 1644

## DETAILED ACTION

Page 2

- 1. A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed 6/27/08 in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's amendment and remarks filed 3/27/08 have been entered.
- 2. Claims 65-75 are pending.
- 3. In view of Applicant's amendments the previous rejections, parts A) and D), under the first paragraph of 35 U.S.C. 112 have been withdrawn.
- 4. Claims 65 and 71 are objected to; in the last line of the claims "CH1b" should presumably be "anti-CD1b".
- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 65-75 stand rejected under 35 U.S.C. § 112, first paragraph, as the specification does not contain a written description of the claimed invention, in that the disclosure does not reasonably convey to one skilled in the relevant art that the inventor(s) had possession of the claimed invention at the time the application was filed. This is a new matter rejection.

As set forth previously, The specification and the claims as originally filed do not provide support for the invention as now claimed, specifically:

- B) The method of Claims 65, 71, and 76 comprising: ... c. performing a morphological analysis to demonstrate the presence of dendritic processes in cells of the culture,
  - C) The method of Claim 65 and 71 comprising:

Application/Control Number: 09/800,448

Art Unit: 1644

 $\dots$  d. performing flow cytometric analysis to demonstrate an immunophenotype of dendritic Langerhans type cells in cells of the culture.

Page 3

Regarding B), Applicant cites paragraphs 54, 30 and 31 (presumably of the pre-grant publication) and Figure 1C.

The cites refer to a specific example (Example 6) of producing human Langerhans cells by a specific method comprising more specific steps than are recited in the claims. Said cite cannot support the more generic claims as are instantly recited.

Regarding C), Applicant cites paragraphs 50 and 51 (again, presumably of the pre-grant publication).

The cites are again from Example 6 wherein cytometric analysis is performed on human Langerhans cells employing specific antibodies. Said cite cannot support the more generic claims as are instantly recited.

Applicant argues that the rejections should be withdrawn in view of the new amendments.

A review of the instant amendments shows that Applicant has inserted more of the limitations found only in Example 6 of the specification into parts c. and d. of Claims 65 and 71. A review of the Example reveals, however, that it discloses only a method of generating human dendritic Langerhans cells from human peripheral blood monocytes. Accordingly, this constitutes the introduction of additional new matter into Claim 65. Additionally, the Example is limited to a method employing only autologous platelets in RPMI-1640 medium with or without 2% fetal calf serum. Accordingly, this constitutes the introduction of additional new matter into Claim 71. So while some of these limitations are recited in some of the claims, all of the limitations are recited in none of the claims.

- 7. No claim is allowed.
- 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara, Ph.D. can be reached on (571) 272-0878.
- 9. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application

Application/Control Number: 09/800,448

Art Unit: 1644

Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

Page 4

/G.R. Ewoldt/
G.R. Ewoldt, Ph.D.
Primary Examiner
Technology Center 1600